Chemical Structure (Ibrance 01)
Ibrance Tablet, Film Coated
Product Images NDC 0069-0486
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Ibrance (NDC 0069-0486). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Ibrance 02)
This appears to be a comparison of two treatments for breast cancer patients: "pabociclibrletrozole" versus "placeborletrozole". The chart shows the progression-free survival probability over the course of 27-33 months for a group of patients in each treatment group. However, some of the text is not clear, and it is difficult to infer more details about the study or the results.*
Figure 2 (Ibrance 03)
Figure 3 (Ibrance 04)
The text shows a chart displaying the Overall Survival Probability for patients treated with either palbociclib and fulvestrant or a placebo and fulvestrant. The chart presents the time (in months) on the x-axis and the survival probability (in percentage) on the y-axis. The number of patients at risk for each treatment is also shown.*
Logo (Ibrance 05)
This text is a description of the distributor, Pfizer Labs, which is a division of Pfizer Inc. The address given is NY, NY 10017.*
Logo (Ibrance 06)
This is a description of a product's distributor. The text indicates that Pfizer Labs is distributing the product and is a division of Pfizer Inc located in New York.*
Principal Display Panel (Topper Card)
Your Monthly Box includes 3 weekly packs of IBRANGE (palbociclib) medication to help track your treatment cycle. The provided text also includes a treatment cycle tracker to help fill in dates for Weeks 1 through 3. However, the text also includes a random set of letters and numbers at the end, which makes it unclear if this information is complete or useful.*
Principal Display Panel (75 mg Tablet Dose Pack)
IBRANCE is a medication provided in tablet form that contains 75 mg of palbociclib. The medication is intended for use with a recommended dosage consisting of one tablet followed by seven days off treatment. The weekly pack contains a total of seven tablets. It is advised to store the medication in its original blister pack at temperatures between 20°C and 25°C. Additional information on temperature allowances for storage can be found accompanying the medication. The medication is distributed by Pfizer Labs, which is a division of Pfizer located in New York.*
Principal Display Panel (75 mg Tablet Dose Pack Carton)
Principal Display Panel (100 mg Tablet Dose Pack)
IBRANCE is a medication indicated for the treatment of certain types of cancer that should be taken for 7 days as indicated. For more information visit the website www.ibrance.com. The medication comes in a package containing 7 pills of 100 mg each to be stored at a temperature between 15°C to 30°C. The medication is distributed by Pfizer Inc. However, the output seems to be incomplete as some text is not clear.*
Principal Display Panel (100 mg Tablet Dose Pack Carton)
Description not available.*
Principal Display Panel (125 mg Tablet Dose Pack)
IBRANCE® (palbociclib) tablets are contained in a weekly pack. Each tablet contains 125mg of palbociclib. The recommended dosage is one tablet followed by a 7-day treatment. These tablets should be stored in their original blister pack with accompanying storage conditions between 20°C and 25°C. Excursions are permitted between 15°C and 30°C. For more information, visit www.IBRANCE.com. Distributed by Pfizer Labs, a division of Pfizer Inc., New York, NY 10017.*
Principal Display Panel (125 mg Tablet Dose Pack Carton)
The text contains a mix of letters, numbers, symbols, and gibberish. It is not available for generating a useful description.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
